Home Healthcare IT Antitumor Antibiotics Market Trends, Growth, & Share-2031

Antitumor Antibiotics Market

Antitumor Antibiotics Market Size, Share & Trends Analysis Report By Drug Type (Anthracyclines, Chromomycins, Miscellaneous), By Distribution Channel (Hospitals, Retail Pharmacies, Online) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032

Report Code: SRHI222DR
Study Period 2020-2032 CAGR 5.3%
Historical Period 2020-2022 Forecast Period 2024-2032
Base Year 2023 Base Year Market Size USD XX Billion
Forecast Year 2032 Forecast Year Market Size USD XX Billion
Largest Market Europe Fastest Growing Market Asia Pacific
The sample report only takes 30 secs to download, no need to wait longer.

Market Overview

Global antitumor antibiotic market size accounted for around USD 3,000 million in 2017 and is expected to grow at a CAGR of 5.3% during the forecast period, (2019–2026). 

Antitumor antibiotic drugs are used in chemotherapy to treatment different types of cancers such as leukemia, bladder cancer, and others. In every three minutes a person is diagnosed with leukemia in the U.S and it is also one of the most common cancers among children. Around 437,033 new cases of leukemia were diagnosed in 2018 worldwide, the American Institute for Cancer research. Today, the market is packed with a wide range of chemotherapy drugs, let it be single drug or combination of drugs.  Anthracyclines is one of the leading types of antitumor antibiotic drugs and has been effectively used for treating leukemia, ovarian, breast, stomach, and other cancer therapies. Anthracyclines are also used in breast cancer treatment. Over 13 million electronic medical records exist in the U.S. for cancer patients.

Regional Analysis

Geographically, the global antitumor antibiotic market is segmented into four regions: the Americas, Europe, Asia Pacific, and the Middle East & Africa (MEA).

From the past few years, the overall prevalence of cancer has grown exponentially across the Americas. Currently, the region is burdened with high demand for effective drugs to treat this disease. In a study, it has been found that the prevalence of cancer is higher among older patients in the U.S. For instance, around 87% of cancers are diagnosed in the people above 50 years. This has again increased the economic burden on the country. In 2015, the direct medical cost for cancer treatment was accounted for around USD 80.2 billion in the U.S.  So far, numerous drugs have been introduced to the market and many more are in pipeline. For instance, 14 new active substances for cancer therapeutics were launched in 2017 and 11 of them were categorized under breakthrough therapy by the Food and Drugs Administration.

Asia Pacific is expected to witness significant growth during the forecast period. The region has large cancer population. Prevalence of breast cancer in Asia is much higher than western countries, which is mainly attributed to rapid lifestyle changes, especially fertility pattern. In addition, lack of awareness is another prominent concern in the region. Apart from this, some well-educated countries such as South Korea and Japan have stigmatized the breast cancer issue leading to high untreated population. To tackle this crucial situation, policymakers need to follow a comprehensive plan, which include screening, affordable drugs, and better healthcare policies. Governments in the region are focused on providing sustainable treatment. For instance, India has 27 region cancer centers, and the government provides up to 50,000 financial support to poor patients. China has reduced import tariff on major cancer drugs, including 39 patented drugs to reduce the prices of these drugs. Moreover, Japan has simplified the average development times and the regulatory approval process for new molecules to encourage better treatment alternatives.

Report Scope

Report Metric Details
Segmentations
By Drug Type
  1. Anthracyclines
    1. Daunorubicin
    2. Doxorubicin
    3. Idarubicin
    4. Epirubicin
  2. Chromomycins
    1. Dactinomycin
    2. Plicamycin
  3. Miscellaneous
    1. Mitomycin
    2. Bleomycin
By Distribution Channel
  1. Hospitals
  2. Retail Pharmacies
  3. Online
Company Profiles Astellas Pharma Inc. (Japan) Johnson & Johnson Services Inc. (U.S.) Bristol-Myers Squibb Company (U.S.) Novartis AG (Switzerland) Pfizer Inc. (U.S.) Merck & Co. Inc. (U.S.) AG Scientific (U.S.) Amgen Inc. (U.S.).
Geographies Covered
North America U.S. Canada
Europe U.K. Germany France Spain Italy Russia Nordic Benelux Rest of Europe
APAC China Korea Japan India Australia Taiwan South East Asia Rest of Asia-Pacific
Middle East and Africa UAE Turkey Saudi Arabia South Africa Egypt Nigeria Rest of MEA
LATAM Brazil Mexico Argentina Chile Colombia Rest of LATAM
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Segmental Analysis

Global antitumor antibiotic market is segmented by drug type and distribution channel.

By drug type, the market is segmented into anthracyclines, chromomycins, and miscellaneous. Anthracyclines is projected to witness huge demand in the coming years on account of growing prevalence of leukemia and bladder cancers. Moreover, its use in combination therapy has shown promising results during treatment. Anthracycline in chemo regime has shown better results than without anthracycline chemotherapy. As per study conducted on 4,130 women suffering from breast cancer for anthracyclines therapy showed that women lived longer without reassurance of cancer.

By distribution channel, the antitumor antibiotic market is segmented into hospitals, retail pharmacies, and online. Hospitals are holding the major grip on market, which be a result of easy availability of drugs and large patient population visiting hospitals.

Market Size By Drug Type

Market Size By Drug Type
  • Anthracyclines
  • Chromomycins
  • Miscellaneous
  • Top Key Players

    Antitumor Antibiotics Market Share of Key Players

    Antitumor Antibiotics Market Share of Key Players
    Astellas Pharma Inc. (Japan) Johnson & Johnson Services Inc. (U.S.) Bristol-Myers Squibb Company (U.S.) Novartis AG (Switzerland) Pfizer Inc. (U.S.) Merck & Co. Inc. (U.S.) AG Scientific (U.S.) Amgen Inc. (U.S.). Others

    Frequently Asked Questions (FAQs)

    What is the estimated growth rate (CAGR) of the Antitumor Antibiotics Market?
    Antitumor Antibiotics Market size will grow at approx. CAGR of 5.3% during the forecast period.
    Some of the top prominent players in Antitumor Antibiotics Market are, Astellas Pharma Inc. (Japan), Johnson & Johnson Services Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Merck & Co. Inc. (U.S.), AG Scientific (U.S.), Amgen Inc. (U.S.)., etc.
    Europe has been dominating the Antitumor Antibiotics Market, accounting for the largest share of the market.
    The Asia Pacific region is projected to exhibit the highest rate of growth in the Antitumor Antibiotics Market.
    The global Antitumor Antibiotics Market report is segmented as follows: By Drug Type, Distribution Channel


    We are featured on :